Immunogenic detoxified mutants of cholera toxin

Details Immunogenic detoxified mutants of cholera toxin Immunogenic detoxified mutants of cholera toxin

2011-01-18

2011-01-18

Navarro, Mark (Department: 1645)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C435S069300, C435S252330

Reexamination Certificate

active

07872114

ABSTRACT:
An immunogenic detoxified protein comprising the amino acid sequence of subunit A of a cholera toxin (CT-A) or a fragment thereof or the amino acid sequence of subunit A of anEscherichia coliheat labile toxin (LT-A) or a fragment thereof wherein the amino acids at, or in positions corresponding to Ser-63 and Arg-192 are replaced with another amino acid. The immunogenic detoxified protein is useful as vaccine forVibrio choleraeor an enterotoxigenic strain ofEscherichia coliand is produced by recombinant DNA means by site-directed mutagenesis.

REFERENCES:
patent: 4328209 (1982-05-01), Finkelstein et al.
patent: 4666837 (1987-05-01), Harford et al.
patent: 4935364 (1990-06-01), Kaper et al.
patent: 5182109 (1993-01-01), Tamura et al.
patent: 5427788 (1995-06-01), Rappuoli et al.
patent: 5601827 (1997-02-01), Collier et al.
patent: 5668255 (1997-09-01), Murphy
patent: 5770203 (1998-06-01), Burnette et al.
patent: 5874287 (1999-02-01), Burnette et al.
patent: 6019982 (2000-02-01), Clements et al.
patent: 6033673 (2000-03-01), Clements
patent: 6149919 (2000-11-01), Domenighini et al.
patent: 6413523 (2002-07-01), Clements
patent: 6436407 (2002-08-01), Clements et al.
patent: 6440423 (2002-08-01), Clements et al.
patent: 7056521 (2006-06-01), Barchfeld et al.
patent: 7063852 (2006-06-01), Clements
patent: 7070781 (2006-07-01), Rappuoli
patent: 7115730 (2006-10-01), Pizza et al.
patent: 7285276 (2007-10-01), Murdin et al.
patent: 7332174 (2008-02-01), Green et al.
patent: 7384640 (2008-06-01), Holmes et al.
patent: 7632513 (2009-12-01), Pizza et al.
patent: 2002/0044939 (2002-04-01), Pizza et al.
patent: 2003/0113345 (2003-06-01), Clements
patent: 2003/0176653 (2003-09-01), Mason et al.
patent: 2004/0137017 (2004-07-01), Pizza et al.
patent: 2004/0176571 (2004-09-01), Green et al.
patent: 2004/0181036 (2004-09-01), Green et al.
patent: 2005/0106178 (2005-05-01), O'Hagan
patent: 2005/0186266 (2005-08-01), Murdin et al.
patent: 2006/0008476 (2006-01-01), Pizza et al.
patent: 2006/0051378 (2006-03-01), Guidice et al.
patent: 2006/0057155 (2006-03-01), Masignani et al.
patent: 2006/0140981 (2006-06-01), Jonsdottir
patent: 2006/0251675 (2006-11-01), Hagen
patent: 2008/0063665 (2008-03-01), Oster et al.
patent: 2008/0112965 (2008-05-01), Murdin et al.
patent: 0396964 (1990-11-01), None
patent: 0462534 (1991-12-01), None
patent: 9320454.3 (1994-10-01), None
patent: 9324743.5 (1994-10-01), None
patent: WO 92/19265 (1992-11-01), None
patent: 93/13202 (1993-07-01), None
patent: WO 93/13202 (1993-07-01), None
patent: WO 95/09649 (1995-04-01), None
patent: WO 95/34323 (1995-12-01), None
patent: WO 96/06627 (1996-03-01), None
patent: WO 99/58145 (1999-11-01), None
patent: WO 00/18434 (2000-04-01), None
Mekalanos, John J. et al, Nature, Dec. 1981, pp. 551-557, vol. 306(5943).
Pizza et al, Mol. Microbiology, Oct. 1994, pp. 51-60, vol. 14(1).
Fontana, Maria Rita et al, Infection and Immunity, vol. 63(6), pp. 2356-2360, Jun. 1995.
Clement et al, reference of record.
Grant et al, Infection and Immunity, vol. 62(10), pp. 4270-4278, Oct. 1994.
Fontana, Maria Rita et al, Infection and Immunity, vol. 63(6), pp. 2356-2360, Jun. 1995, Construction of Nontoxic Derivatives of Cholera toxin and Characterizatio not the Immunological Response against the A subunit.
Boslego, J.W. et al., Vaccines and Immunotherapy, Chapter 17, 1991, 211-223.
Burnette, W.N. et al., “Site-specific mutagenesis of the catalytic subunit of cholera toxin: substituting lysine for arginine 7 causes loss of activity,”Inf.&Immun., 1991, 59:4266-4270.
Dallas, W.S. et al., “Cistrons encodingEscherichia coliheat-labile toxin,”J. Bacteriol., 1979, 139:850-858.
Dente, L. et al., “pEMBL: a new family of single stranded plasmids,”Nucleic Acids Res., 1983 11(6):1645-1655.
Domenighini, M. et al., “Identification of errors among database sequence entries and comparison of correct amino acid sequences for the heat-labile enterotoxins ofEschericia coliandVibrio cholerae,” Mol. Microbial., 1995, 15(6):1165-1167.
Domenighini, M. et al., “Common features of the DNA-binding and catalytic site of ADP-ribosylating toxins,”Mol. Microbiol., 1994, 14(1):41-50.
Dickinson, B. et al., “Dissociation ofEscherichia coliheat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity,”Infection and Immunity, 1995, 63(5):1617-1623.
Donta, S., “Detection of heat-labileEscherichia colienterotoxin with the use of adrenal cells in tissue culture,”Science,1974, 183:334-336.
Fontana, M.R. et al., “Construction of nontoxic derivatives of cholera toxin and characterization of the immunological response against the A subunit,”Infection and Immunity, 1995, 63(6):2356-2360.
Grant, C. et al., “Role of trypsin-like cleavage at arginine 192 in the enzymatic and cytotonic activities ofEscherichia coliheat-labile enterotoxin,”Infection and Immunity, 1994, 62(10):4270-4278.
Grant, C.C.R. et al., “Effect of single amino acid changes on the ADP-ribosyltransferase activity ofEscherichia coliheat-labile toxin subunit A,”92ndGen. Meet. Am. Soc. Microbiol., 1992, Abstract B278, 74.
Harford, S. et al., “Inactivation of theEscherichia coliheat-labile enterotoxin by in vitro mutagenesis of the A-subunit gene,”Eur. J. Biochem., 1989, 183:311-316.
Hase, C. et al., “Construction and characterization of recombinantVibrio choleraestrains producing inactive cholera toxin analogs,”Infection and Immunity, 1994, 62(8):3051-3057.
Hirst, T. et al., “Transient entry of enterotoxin subunits into the periplasm occurs during their secretion fromVibrio cholerae,” J. Bacteriol., 1987, 169(3):1037-1045.
Holmgren, J. et al., “Oral immunization against cholera,”Curr. Top. Microbiol. Immunol., 1998, 146:197-204.
Jobling, M.G. et al., “Analysis of the structure and function of cholera toxin A subunit,”Abstr. Gen. Meet. Am. Soc. Microbiol., 1991, 91(0), 59, #B205.
Kaslow, H.R. et al., “Effects of site-directed mutagenesis on cholera toxin A1 subunit ADP-ribosyltransferase activity,”92ndGen. Meet. Am. Soc. Microbiol., 1992,Asbract B291, 74.
Kaslow, H.R. et al., “Site-specific mutagenesis of the pertussis toxin S1 subunit gene: effects of amino acid substitutions involving residues 50-58,”Vaccine Research, 1992, 1(1):47-54.
Lai, C.Y. et al., “Location and amino acid sequence around the ADP-ribosylation site in the cholera toxin active subunit A1,”Biochem. Biophys. Res. Comm., 1983, 116:341-348.
The Lancet, Sep. 27, 1986, 328(8509):722-723, “Oral Cholera Vaccines”.
Lebacq-Verheyden, A.M. et al., “Posttranslation processing of endogenous and of baculovirus-expressed human gastrin-releasing peptide precursor,”Mol. Cell. Biol., 1988, 8:3129-3135.
Lobet, Y. et al., “Effect of site-directed mutagenic alterations on ADP-ribosyltransferase activity of the A subunit ofEscherichia coliheat-labile enterotoxin,”Inf.&Immun., 1991, 59:2870-2879.
Loosemore, S.M. et al., “Engineering of genetically detoxified pertussis toxin analogs for development of a recombianant whooping cough vaccine,”Infection and Immunity, 1990, 58(11):3653-3662.
Lycke, N. et al., “The adjuvant effect ofVibrio choleraeandEscherichia coliheat-labile enterotoxins is linked to their ADP-ribosyltransferase activity,”Eur. J. Immunol., 1992, 22:2277-2281.
Magagnoli, C. et al., “Mutations in the A subunit affect yield, stability, and protease sensitivity of nontoxic derivatives of heat-labile enteroxotin,”Infection and Immunity, 1996, 64(12):5434-5438.
Mekalanos, J.J. et al., “Cholera toxin genes: nucleotide sequence, deletion analysis and vaccine development,”Nature, 1983, 306:551-557.
Molecular Microbiology, 1995, 15(6):1165-1167, “MicroCorrespondence”.
Okamoto, J. et al., “Effect of substitution of glycine for arginine at position 146 of the A1 subunit on biological activity ofEsc

Affiliated with

Also associated with

Rating

Immunogenic detoxified mutants of cholera toxin does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Immunogenic detoxified mutants of cholera toxin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunogenic detoxified mutants of cholera toxin will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2732172